The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Quiz|Articles|September 19, 2026
OncLive Weekly News Quiz (9/19/2026): Did You Catch the Latest NETs, Lung, Mastocytosis, and Pancreatic Cancer News?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA approved lutetium Lu 177 dotatate injection (Bexlutry) for adults with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, based on the ERASMUS study. What overall response rate was observed among the 145 evaluable patients?
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
EU Approval Reccomended by CHMP for Senaparib in First-Line Advanced Ovarian Cancer
3
CHMP Recommends Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
CHMP Backs Perioperative Pembrolizumab Plus Enfortumab Vedotin for Resectable MIBC
5